Pdt Partners, LLC Glycomimetics Inc Transaction History

Pdt Partners, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$1.8 - $2.39 $148,140 - $196,697	-82,300 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$2.89 - $4.22 $88,723 - $129,553	30,700 Added 59.5%	82,300 $248,000
Q4 2020 Feb 16, 2021	BUY	$2.69 - $4.24 $138,804 - $218,784	51,600 New	51,600 $194,000
Q3 2020 Nov 16, 2020	SELL	$3.07 - $5.0 $128,633 - $209,500	-41,900 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$1.83 - $5.41 $279 - $827	-153 Reduced 0.36%	41,900 $96,000
Q4 2019 Feb 14, 2020	BUY	$4.03 - $6.5 $169,473 - $273,344	42,053 New	42,053 $222,000

17.8M

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $16.3M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.